|Bid||131.15 x 100|
|Ask||132.45 x 100|
|Day's Range||127.80 - 136.25|
|52 Week Range||92.65 - 143.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||151.29|
Since the February stock market correction started, Philip Morris International Inc. (NYSE:PM) stock has had a turbulent period of trading. Compare that with a flat stock market — both Philip Morris and Altria Group, Inc. (NYSE:MO) stocks have been decimated. Meanwhile, cannabis stocks like GW Pharmaceuticals plc (NASDAQ:GWPH) have fared much better and are in line with the stock market in general.
IN THE NEWS The big news on Thursday was that Amazon.com, Inc. (NASDAQ: AMZN ) had reached 100 million Prime subscribers. It’s a major milestone for Amazon, and it took the company just 13 years to reach: ...
A special FDA committee unanimously approved GW Pharmaceuticals' cannabis-based anti-seizure drug, the firm said midday Thursday.
The drug, Epidiolex, was developed by London's GW Pharmaceuticals and is a pharmaceutical-grade form of cannabidiol, or CBD, an oil found in marijuana plants. GW grows the plant in greenhouses and purifies out the CBD.
An advisory panel to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of approving the first cannabis-derived medicine in the country, a childhood epilepsy treatment developed by GW Pharma. The drug, Epidiolex, is derived from cannabidiol (CBD), one of the hundreds of molecules found in the marijuana plant, and an FDA decision is expected by June 27. The FDA panel found that the drug's benefits outweighed the risks to treat patients aged 2 years and older with Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS), rare childhood-onset forms of epilepsy that are among the most resistant to treatment.
WASHINGTON (AP) — A medicine made from the marijuana plant moved one step closer to U.S. approval Thursday after federal health advisers endorsed it for the treatment of severe seizures in children with epilepsy.
An FDA advisory panel recommended approval of what could become the first prescription drug in the U.S. derived from the marijuana plant, as a treatment for people with rare forms of epilepsy.
GW Pharmaceuticals PLC said Thursday it has won a unanimous recommendation from a U.S. Food and Drug Administration advisory committee for the approval of its cannabis-derived drug epidiolex. Epidiolex ...
LONDON and CARLSBAD, Calif., April 19, 2018-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid ...
Epidiolex would be the first drug on the U.S. market derived from the cannabis plant. An outside panel of advisors to the FDA gave a unanimous vote of approval. The medication, which is manufactured by GW Pharmaceuticals, is used in the treatment of seizures associated with childhood epilepsy.
U.S. drug regulators are edging closer to approving the first-ever medicine derived from a marijuana plant, an experimental epilepsy treatment developed by GW Pharmaceuticals Plc. On Thursday, a panel of outside advisers to the Food and Drug Administration unanimously voted that the drug’s benefits outweigh its risk in treating two rare forms of childhood epilepsy. “It’s an enormous milestone,” Orrin Devinsky, who specializes in epilepsy at the New York University Langone Medical Center, said in an interview before the advisory panel meeting.
GW Pharmaceuticals Plc's cannabis-based drug to treat a severe form of childhood epilepsy was unanimously backed on Thursday by an advisory panel to the U.S. Food and Drug Administration. The positive ...
Cronos Group Inc (NASDAQ:CRON) became the first pure-play medical marijuana company to list on an American exchange when it debuted on the Nasdaq in late February. The firm sticks out from the above stocks because its stock behaves much more like a traditional research biotech than a weed-focused REIT or investment fund.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Alcoa Corp (NYSE: AA ) stock was trading higher by ...
Fresh bullishness over the past few trading periods has inspired positive trading in several key global markets. But interestingly enough, a number of optimistic headlines in the budding marijuana industry has led to an even stronger recovery in this popular investing area.
NEW YORK, NY / ACCESSWIRE / April 18, 2018 / Markets continued to rise on Tuesday as investor focus continues to shift from geopolitical concerns to strong corporate earnings from major U.S. companies. ...
GW Pharma spiked to an 11-week high Tuesday after an internal review hinted at the likelihood the FDA will approve its cannabis-based anti-seizure drug.
WASHINGTON (AP) — A closely watched medicine made from the marijuana plant reduces seizures in children with severe forms of epilepsy and warrants approval in the United States, health officials said Tuesday.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) stock was up today on news that the U.S. Food and Drug Administration (FDA) may approve its drug derived from cannabis. The positive bit of news for GWPH stock today comes in the form of a briefing document for an upcoming meeting about epidiolex. This is a drug made by GW Pharmaceuticals for treating seizures that children with certain types of epilepsy can suffer from.
CNBC's Meg Tirrell speaks with Justin Gover of GW Pharmaceuticals on the FDA's unanimous approval of a cannabis-based drug called Epidiolex to treat epilepsy.